BIBLIOGRAFÍA RECOMENDADA
1. Hettiarachchi R, Prins M, Lensing A, Büller H. Low molecular weight heparin versus unfractioned heparin in the initial treatment of venous thromboembolism. Curr Opin Pulmonary Med. 1998; 4: 220-5.
2. Warkentin T, Levine M, Hirsh J, Horsewood P, Roberts R, Gent M, et al. Heparine-induced thrombocytopenia in patients with low-molecular-weigth heparin or unfractioned heparin. N Engl J Med 1995; 332: 1330-5.
3. López-Beret P, Orgaz A, Fontcuberta J, Doblas M, Martínez A, Lozabo G, et al. Low molecular weight heparin versus oral anticoagulants in the long-term treatment of deep venous thrombosis. J Vasc Surg 2001; 33: 77-90.
4. González-Fajardo J, Arreba E, Castrodeza J, Pérez JL, Fernández L, Agundez I, et al. Venographic comparison of subcutaneous low-molecular weight heparin with oral anticoagulant therapy in the long-term treatment of deep venous trombosis. J Vasc Surg 1999; 30: 283-92.
5. Hull RD, Gaham FP, Rollin FB, Mah AF, Burke N, Dear R, et al. Self-managed long-term low-molecular-weight heparin therapy: the balance of benefits and harms. Am J Med 2007; 120: 72-82.
6. Hull RD, Graham FP, Rollin FB, Mah AF, Buke N, Dear R, etal. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med 2006; 119: 1062-72.
7. Daskalopoulus ME, Daskalopoulu SS, Tzortzis E, Sfiridis P, Nikolaou A, Dimitroulis D, et al. Long-trm treatment of deep venous thrombosis with a low molecular weight heparin (tinzaparin): a prospective randomized trial. Eur J Vasc Endovasc Surg 2005; 29: 638-50.